---
title: 'Senior/Principal Scientist, Medicinal Chemistry at Nurix'
canonical: 'https://feeny.ai/job/senior-principal-scientist-medicinal-chemistry-nurix-brisbane-sk240f67bwms'
type: 'job'
last_seen: '2026-10-29'
---

# Senior/Principal Scientist, Medicinal Chemistry at Nurix

- **Company:** Nurix
- **Location:** Brisbane, CA
- **Posted:** 2026-10-22
- **Last confirmed live:** 2026-10-29
- **Apply:** https://job-boards.greenhouse.io/nurix/jobs/8910067002

## Job description

Senior/Principal Scientist, Medicinal Chemistry

## About the Position

We are seeking a talented and highly motivated individual with a strong background in synthetic organic chemistry to join our medicinal chemistry group in the pursuit of degrader-based small molecules to treat patients with unmet medical needs. This individual will design and synthesize novel chemical entities optimized for potency, selectivity, pharmacokinetics and in vivo efficacy, and will engage in rational structure-based drug discovery enabled by our computational and structural biology groups. As a member of a dynamic multi-disciplinary team, this person will collaborate with a broad group of scientists within Nurix and with external collaborators. Additionally, they will contribute to patent, report and scientific publication writing. Furthermore, they will initiate and/or lead process improvements within the chemistry department or cross-functionally.

## Qualifications

- Ph.D. in synthetic organic chemistry with 8 – 10+ years pharmaceutical medicinal chemistry industrial experience.
- Track record of delivering advanced leads/ development candidates.
- Excellent knowledge of medicinal chemistry principles with a solid understanding of the biology and pharmacology of programs, ADME concepts, and series SAR. Able to effectively integrate this knowledge to direct drug discovery programs to phase transitions or series go/no go decisions.
- Strong working knowledge of protein-ligand interactions, conformational and structural analysis. Experienced in partnering closely with computational chemists in the use of computational tools, models and visualization applications.
- Expert in organic synthesis, knowledgeable of the current literature, with strong synthetic problem-solving skills.
- Proven leadership capability in a cross-functional team setting, either as project team leader or co-lead.
- Ability to make inventive contributions towards new chemical target structures or templates for programs and evaluate early screening or literature hits.
- Strong skills in gathering, documenting, and analyzing information from competitive sources such as patents and meetings and using this information to guide program strategy.
- Excellent communication skills and the ability to present rationale, key data, issues and accomplishments to the company.
- Experience supervising direct reports to a high level of productivity and mentoring for career development is a plus.
- Ability to manage priorities and advance multiple projects simultaneously.
- Strong evidence of conceptual thinking and active follow through, recognized by establishing new projects or new directions within projects, new strategies and/or enabling technologies for drug discovery.

Fit with Nurix Culture and Values

- Strong team orientation; highly collaborative
- Ability to function in a dynamic environment
- Solutions and results-oriented focus
- Hands-on approach; resourceful and open to diverse points of view

Location:          Onsite – Brisbane, CA

## About Nurix Therapeutics

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.

## About Nurix

## Company Overview
- **One-liner**: Nurix Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation medicines to outmatch disease by harnessing the cell’s natural protein disposal system.
- **Entity Type**: Public (NASDAQ: NRIX)
- **Headquarters**: San Francisco, California, USA
- **Founded**: 2009
- **Founders**: Not publicly listed as individual founders; the company was spun out from research at UC Berkeley and UC San Francisco.

## Core Business
- **Primary industry**: Biopharmaceuticals / Targeted Protein Degradation
- **Target customers**: B2B (pharma partners) and B2C (patients via clinical trials and eventual commercial therapies); enterprise-level partnerships with major pharma.
- **Mission or purpose statement**: "Writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease." [nurixtx.com](https://www.nurixtx.com/)

## Products & Services
- **Bexobrutideg (NX-5948)**: A potential best-in-class BTK degrader in Phase 1b/2 clinical trials for relapsed/refractory CLL/SLL and chronic spontaneous urticaria. Co-developed and co-commercialized with Roche under a global collaboration announced June 2026. [nurixtx.com](https://www.nurixtx.com/)
- **NX-2127**: A BTK degrader in clinical development for B-cell malignancies.
- **CBL-B Inhibitor (NX-1607)**: An E3 ligase inhibitor designed to activate T cells for immuno-oncology, in Phase 1 clinical trials.
- **IRAK4 Degrader**: A partnered program with Gilead in Phase 1 for inflammatory diseases.
- **STAT6 Degrader**: A partnered program with Sanofi in IND-enabling studies.
- **DEL-AI Discovery Engine**: A proprietary, fully AI-integrated platform combining DNA-encoded libraries (DEL), automated chemistry, and machine learning to design and optimize targeted protein degraders and degrader-antibody conjugates (DACs).

## Market Standing
- **Valuation/Market Cap**: Not publicly available in the provided search results; as a public company (NRIX), market cap fluctuates daily. Check financial platforms for the latest figure.
- **Key Metric**: Annual Revenue (public) — Not publicly available in the provided search results; as a clinical-stage biotech, revenue is typically minimal or pre-revenue. Total funding raised prior to IPO is not detailed in the provided results.
- **Notable Investors/Partners**: Roche (global co-development and co-commercialization collaboration for bexobrutideg, announced June 2026), Gilead (partnered IRAK4 degrader program), Sanofi (partnered STAT6 degrader program).
- **Growth Signals**: Announced a landmark global collaboration with Roche in June 2026 to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology, and neurology. Presented positive Phase 1a/b data for bexobrutideg in CLL/SLL and chronic spontaneous urticaria in 2026. Multiple partnered and wholly owned pipeline programs advancing through clinical and preclinical stages.

## Competitive Advantages
- **Proprietary DEL-AI Discovery Engine**: A fully AI-integrated platform combining DNA-encoded libraries, automated chemistry, and machine learning to design degraders against any protein class, providing a significant speed and innovation advantage. [nurixtx.com](https://www.nurixtx.com/)
- **Unparalleled Ligase Expertise**: Deep understanding of E3 ligase biochemistry and biology, a critical and complex component of the protein degradation mechanism, giving them a unique moat.
- **Multi-Modal Pipeline**: Developing both small molecule degraders and Degrader-Antibody Conjugates (DACs), expanding the therapeutic reach and creating multiple shots on goal.
- **Strong Partnership Network**: Collaborations with top-tier pharma (Roche, Gilead, Sanofi) validate their platform and provide non-dilutive funding and shared risk.

## Strategic Focus
- **Clinical Advancement**: Driving lead asset bexobrutideg through pivotal trials in CLL/SLL and expanding into immunology (chronic spontaneous urticaria) and neurology.
- **Platform Expansion**: Leveraging the DEL-AI engine to develop Degrader-Antibody Conjugates (DACs) for enhanced cell specificity and safety.
- **Pipeline Breadth**: Advancing a multi-modal pipeline across oncology, immunology, and neurology, both wholly owned and through strategic partnerships.
- **Partnership Leverage**: Deepening collaborations with Roche, Gilead, and Sanofi to co-develop and co-commercialize programs, reducing risk and accelerating timelines.

## Why Work Here
- **Culture**: Mission-focused, values-based, and spirited culture emphasizing "breakthrough innovation," "leadership," "accountability," and "zealousness." Employees are encouraged to "think big and act bold." [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Work with Industry Leaders**: The team includes scientific innovators who built the protein degradation field, seasoned executives with biotech scaling expertise, and leading clinicians. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Growth & Impact**: Employees can "wear many hats" and gain broad exposure in a lean, virtual drug developer environment. The company emphasizes career growth and opportunity-rich experiences.
- **Work Policy**: Onsite in Brisbane, CA (San Francisco Bay Area) for most roles, as indicated by job postings. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)
- **Benefits**: Comprehensive health and welfare plans, enhanced parental leave, wellness reimbursement, 401(k) employer match, and a highly collaborative culture. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Engineering/Science Culture**: Described as "mission-focused, values-based, and spirited," with a focus on "intellectual and technical ingenuity" and "intelligent risk-taking." The company is a "virtual drug developer" with a lean internal infrastructure, relying on SaaS and cloud platforms. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)

## Sources
1. [nurixtx.com](https://www.nurixtx.com/)
2. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
3. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)
4. [nurixtx.com](https://www.nurixtx.com/our-story/)

## Other roles at Nurix

- [Director, Quality Assurance](https://feeny.ai/job/director-quality-assurance-nurix-brisbane-3g1nz641gtdv) — Brisbane, CA
- [Scientist I, Bioanalytical](https://feeny.ai/job/scientist-i-bioanalytical-nurix-brisbane-tns4szvd5c07) — Brisbane, CA
- [Senior Research Associate, Preclinical Pharmacology](https://feeny.ai/job/senior-research-associate-preclinical-pharmacology-nurix-brisbane-whtmqmhser7g) — Brisbane, CA
- [Senior Scientist, Medicinal Chemistry](https://feeny.ai/job/senior-scientist-medicinal-chemistry-nurix-the-woodlands-y4nmgjxktsm5) — The Woodlands, TX
- [Scientist I, Medicinal Chemistry](https://feeny.ai/job/scientist-i-medicinal-chemistry-nurix-the-woodlands-bxgy2c1m60vz) — The Woodlands, TX
- [Senior Director, Head of Pharmacovigilance Operations](https://feeny.ai/job/senior-director-head-of-pharmacovigilance-operations-nurix-brisbane-qvx5sf5gc0cv) — Brisbane, CA
- [Senior Manager / Associate Director, Regulatory Affairs CMC (Small Molecules)](https://feeny.ai/job/senior-manager-associate-director-regulatory-affairs-cmc-small-molecules-nurix-pp3fh8jc68k1) — Brisbane, CA
- [Administrative Assistant, Clinical Development (Contract)](https://feeny.ai/job/administrative-assistant-clinical-development-contract-nurix-brisbane-6rnsp2fj2vte) — Brisbane, CA
- [Administrative Assistant, CMC (Contract)](https://feeny.ai/job/administrative-assistant-cmc-contract-nurix-brisbane-cgkssyzb35sq) — Brisbane, CA
- [Associate Director, Regulatory & Medical Writing](https://feeny.ai/job/associate-director-regulatory-medical-writing-nurix-brisbane-2ges8w25nvka) — Brisbane, CA